16.07.2012 - German pharmaceutical and chemical company Bayer sells the business with controversially debated drug Trasylol. The privately-held Dutch pharma The Nordic Group receives the worldwide marketing rights - except the US-territory.
The purchase price for Trasylol was not specified. In late 2008, health authorities in Germany and the United States told Bayer to stop distributing the aprotinin drug anywhere else. The trypsin inhibitor, which accounted for about EUR150m in annual sales, was used for complicated heart and liver surgery to reduce blood loss. In February this year, however, the EMA lifted the sales stop. The study results leading to the market ban had been incorrect said the Committee for Human Medicinal Products (CHMP). This positive opinion is expected to be ratified by the European Commission later in 2012. In Canada, the marketing stop had already been lifted in 2011. The Nordic Group is a European pharmaceutical company in private hands. Nordic claims to grow at an annual average rate of 20 percent. The company's focus is on niche products for hospitals and medicines for rare diseases.
12.05.2015 US pharma is coming to European biotech to fill their pipeline. Pfizer is paying €77.5m for an option on Dutch AM-Pharma, while Juno Therapeutics acquired German biotech Stage Cell Therapeutics for around €72m.
26.05.2015 The Finnish Medicines Agency Fimea has joined the Dutch MEB in its stance on the interchangeability of biosimilars. The Fimea now sees physician-driven switching of biologics as unproblematic.
20.05.2015 The Scottish Government has announced it will double the amount of funds for rare diseases. The New Medicines Fund that was created last year for this purpose will be increased to £80m (€112m).
30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.
SuperScript® III Reverse Transcriptase (RT) is a proprietary mutant of SuperScript® II RT that is active at 50°C and has a half-life of 220 minutes, providing increased specificity with gene-specific primers (GSPs) and the highest cDNA yield of all RTs. more